Skip to content
The Kids Research Institute Australia logo
Donate

No results yet

Search

News & Events

Finding answers for Tenaya: from a sore throat to open-heart surgery

When Katrina took her daughter Tenaya to the local emergency department for the fourth time, she was determined she wouldn’t be leaving without answers.

News & Events

National honour for The Kids Director

Leading paediatrician, infectious diseases specialist and Executive Director of The Kids Research Institute Australia, Professor Jonathan Carapetis, has been recognised for his significant contribution towards medical research with the award of Member of the Order of Australia (AM).

News & Events

World-first video trial to help babies at risk of autism thrive

Video technology is helping researchers learn more about the early communication style of infants with a family history of autism, ADHD or intellectual disability.

News & Events

National guideline provides uniform approach to autism diagnosis

In October 2018, the Autism CRC released A National Guideline for the Assessment and Diagnosis of Autism Spectrum Disorders in Australia.

News & Events

Congratulations to Professor Helen Milroy – WA’s 2021 Australian of the Year

The Kids Research Institute Australia congratulates Professor Helen Milroy on being named Western Australia’s 2021 Australian of the Year.

Research

Generating evidence to inform responsive and effective actions for Aboriginal and Torres Strait Islander adolescent health and well-being: a mix method protocol for evidence integration 'the Roadmap Project'

Australia does not have a national strategy for Aboriginal and Torres Strait Islander adolescent health and as a result, policy and programming actions are fragmented and may not be responsive to needs. Efforts to date have also rarely engaged Aboriginal and Torres Strait Islander people in co-designing solutions. The Roadmap Project aims to work in partnership with young people to define priority areas of health and well-being need and establish the corresponding developmentally appropriate, evidence-based actions.

Research

Prevalence, distribution, and inequitable co-occurrence of mental ill-health and substance use among gender and sexuality diverse young people in Australia: epidemiological findings from a population-based cohort study

To estimate the prevalence, distribution, and co-occurrence of mental ill-health and substance use among gender and sexuality diverse young people relative to their cisgender and heterosexual peers in Australia using population-level, nationally representative data.

Research

Effects of ganaxolone on non-seizure outcomes in CDKL5 Deficiency Disorder: Double-blind placebo-controlled randomized trial

CDKL5 deficiency disorder (CDD) is a rare developmental and epileptic encephalopathy. Ganaxolone, a neuroactive steroid, reduces the frequency of major motor seizures in children with CDD. This analysis explored the effect of ganaxolone on non-seizure outcomes. 

Research

Prevalence of tuberculosis infection among contacts of drug-resistant tuberculosis patients: A systematic review and meta-analysis

Contact investigations with drug-susceptible tuberculosis (DS-TB) patients have demonstrated a high prevalence of tuberculosis infection (TBI). However, the prevalence of TBI among individuals in close contact with drug-resistant tuberculosis (DR-TB) patients is poorly understood. This systematic review and meta-analysis aimed to determine the prevalence of TBI among household and non-household contacts of DR-TB patients.

Research

Patient-advocate-led global coalition adapting fit-for-purpose outcomes measures to assure meaningful inclusion of DEEs in clinical trials

Existing clinical tools that measure non-seizure outcomes lack the range and granularity needed to capture skills in developmental and epileptic encephalopathy (DEE)-affected individuals who also fall in the severe to profound range of intellectual disability. This effectively excludes those with severe impairments from clinical trials, impeding the ability of sponsors to evaluate disease-modifying therapies.